Clinical Study of 18F-Alfatide Injection PET/CT
Summary
This is a multicenter, open, non-inferiority Phase III clinical study to evaluate the efficacy of 18F-Alfatide Injection PET/CT compared with 18F-FDG PET/CT in the diagnosis of lymph node metastasis in non-small cell lung cancer. This trial will include 428 patients with non-small cell lung cancer confirmed by imaging, histopathology and/or cytology or highly suspected by investigators, suspected lymph node metastasis and proposed radical surgery and lymph node dissection. Eligible subjects will receive 18F-Alfatide Injection PET/CT and 18F-FDG PET/CT scans within 1 week. Subjects will undergo relevant security checks before and after each scan. The subjects underwent radical surgery and lymph node dissection within 2 weeks of completing both scans, and the obtained lymph nodes were pathologically examined as the gold standard to compare the diagnostic efficacy of 18F-Alfatide versus 18F-FDG for lymph node metastasis.
Timeline
- Start
- 2024-08
- Primary completion
- 2026-08
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-Alfatide | Diagnostic / imaging agent | 0.1 unknown | Intravenous |
| Subject | 18F-Alfatide | Diagnostic / imaging agent | 0.15 unknown | Intravenous |
| Subject | 18F-FDG | Diagnostic / imaging agent | 5 unknown | Intravenous |
| Subject | 18F-FDG | Diagnostic / imaging agent | 10 unknown | Intravenous |